MLN4924: NEDD8-Activating Enzyme Inhibitor Illuminates Non-Cullin Neddylation in Cancer Research

Introduction

The ubiquitin-proteasome system (UPS) and its regulatory modifications, notably neddylation, have become central to understanding protein homeostasis in cancer. Neddylation, the covalent attachment of the ubiquitin-like modifier NEDD8 to target proteins, is mediated by a cascade of enzymes: the NEDD8-activating enzyme (NAE, E1), NEDD8-conjugating enzymes (E2s), and substrate-specific NEDD8-E3 ligases. Aberrant neddylation contributes to tumorigenesis, with overactivation observed in various cancers. The development of MLN4924 (also known as pevonedistat), a potent and selective NAE inhibitor, has revolutionized the study of this pathway, allowing researchers to dissect the roles of neddylation in cell cycle regulation, cullin-RING ligase (CRL) activity, and emerging non-cullin substrates in solid tumor models.

Mechanism of Action: Selective NAE Inhibition and the Neddylation Pathway

MLN4924 is a small molecule inhibitor that targets the NAE with remarkable specificity (IC₅₀ = 4 nM), competitively binding to the nucleotide-binding site and blocking the initiation of NEDD8 activation. This selective NAE inhibitor for cancer research prevents the formation of NEDD8~Ubc12 thioester intermediates and ultimately suppresses NEDD8 conjugation to cullins and other substrates. The disruption of cullin neddylation leads to inactivation of CRL E3 ubiquitin ligases and accumulation of their substrates, such as the replication licensing factor CDT1, resulting in cell cycle defects, DNA re-replication, and apoptosis. MLN4924 demonstrates high selectivity over related E1 enzymes (UAE, SAE, UBA6, ATG7), ensuring minimal off-target effects and making it a valuable experimental tool for dissecting neddylation-dependent processes in cancer biology.

Expanding the Scope: Non-Cullin Substrates and Tumorigenesis

While the canonical role of neddylation involves activation of cullin-RING ligases (CRLs), recent findings have illuminated the modification of non-cullin substrates with profound implications for cancer progression. Notably, a recent study by Zhang et al. (The EMBO Journal, 2025) identified the small GTPase RHEB as a neddylation substrate of the UBE2F-SAG axis. RHEB neddylation enhances mTORC1 activity, driving cell growth and liver tumorigenesis. Genetic ablation of UBE2F in murine liver models impaired RHEB neddylation, inactivated mTORC1, and attenuated tumor development, underscoring the therapeutic potential of neddylation pathway inhibition beyond cullin-RING ligase regulation.

This paradigm shift broadens the significance of NAE inhibition: MLN4924, by blocking the upstream neddylation pathway, not only impairs CRL-mediated ubiquitination but may also affect the modification and function of non-cullin substrates such as RHEB, with downstream consequences for oncogenic signaling networks.

MLN4924 in Cancer Biology Research: Preclinical Evidence and Applications

Preclinical studies leveraging MLN4924 have demonstrated its broad utility in cancer biology research, particularly in the context of solid tumor models. In vitro, MLN4924 induces potent, dose-dependent inhibition of NAE activity in various cell lines, including HCT-116 colorectal carcinoma cells, leading to accumulation of CRL substrates and cell cycle arrest. In vivo, subcutaneous administration of MLN4924 (30–60 mg/kg) in xenograft models such as HCT-116, H522, and Calu-6 lung carcinoma results in significant tumor growth inhibition with minimal systemic toxicity or weight loss. These findings highlight the compound's pharmacological selectivity, pharmacodynamic efficacy, and tolerability in solid tumor contexts.

Beyond its impact on cullin substrates, the potential for MLN4924 to modulate non-cullin neddylation—such as the RHEB-mTORC1 axis—opens new avenues for interrogating the roles of neddylation in cell signaling, metabolic reprogramming, and resistance mechanisms in cancer. This is particularly relevant given the upregulation of mTORC1 in approximately half of hepatocellular carcinomas and its association with poor prognosis (Zhang et al., 2025).

Technical Considerations for Laboratory Use

MLN4924 is provided as a solid (molecular weight: 443.53 Da), with high solubility in DMSO (≥22.18 mg/mL) and ethanol (≥42.2 mg/mL), but is insoluble in water. It should be stored at −20°C, with prepared solutions recommended for short-term use to preserve bioactivity. These properties render MLN4924 suitable for a variety of cellular and in vivo applications, and its robust selectivity profile enables precise mechanistic studies targeting NAE-dependent processes.

Implications for Anti-Cancer Therapeutic Development

The use of selective NAE inhibitors such as MLN4924 in preclinical models has provided critical insights into the therapeutic potential of neddylation pathway inhibition in oncology. By blocking CRL-mediated protein turnover, MLN4924 induces the accumulation of cell cycle regulators and pro-apoptotic factors, sensitizing tumor cells to DNA damage and promoting cell death. Importantly, the emerging recognition of non-cullin neddylation—such as RHEB modification and its impact on mTORC1—suggests that the therapeutic scope of NAE inhibition may extend to dampening oncogenic signaling pathways not previously associated with the UPS.

These mechanistic revelations support the rationale for combining MLN4924 with other targeted therapies, such as mTOR inhibitors or agents targeting metabolic vulnerabilities, to enhance anti-tumor efficacy and overcome resistance in solid tumors. The compound's favorable tolerability profile in xenograft studies further strengthens its translational prospects for anti-cancer therapeutic development.

Emerging Research Directions: Integrating Neddylation and Tumor Metabolism

The intersection of neddylation, cell cycle regulation, and metabolic signaling is an area of burgeoning interest. As demonstrated in the reference study (Zhang et al., 2025), UBE2F-SAG-mediated RHEB neddylation enhances mTORC1-driven anabolic metabolism and tumorigenesis. The ability of MLN4924 to globally inhibit neddylation presents an opportunity to interrogate these metabolic dependencies in cancer. Future research employing MLN4924 could elucidate how neddylation shapes not only proteostasis but also metabolic flux, autophagy, and resistance to metabolic stress in solid tumor models.

Conclusion

MLN4924 has established itself as a cornerstone tool for dissecting the neddylation pathway in cancer biology research. Its high selectivity for NAE, robust inhibition of CRL activity, and capacity to impact both cullin and non-cullin neddylation events make it indispensable for investigating the multifaceted roles of this post-translational modification in tumorigenesis. The recent identification of RHEB as a neddylation substrate linking UPS regulation to mTORC1 signaling, as reported by Zhang et al. (2025), underscores the expanding landscape of neddylation biology and the translational relevance of NAE inhibition for anti-cancer therapeutic development.

This article extends and differentiates itself from prior works such as "MLN4924 and Neddylation Pathway Inhibition: Novel Insight..." by focusing on the emerging roles of non-cullin neddylation substrates—specifically RHEB and its regulation of mTORC1—in tumor growth and metabolism. While previous articles have detailed mechanistic inhibition of CRLs and cell cycle arrest, this piece integrates recent evidence linking neddylation to metabolic signaling, providing a forward-looking perspective on how MLN4924 enables new research directions in cancer biology and therapeutic innovation.